CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 80 enrolled
Drug / intervention
AbobotulinumtoxinA dose 1 +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04080882
NCT04080882Phase 2Completed

A Multicenter, Randomized, Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Moderate to Severe Platysmal Bands

Galderma R&D·interventional·Posted Sep 6, 2019·Updated Aug 26, 2022

In Brief

A Phase 2 clinical trial evaluating AbobotulinumtoxinA dose 1, Placebo, and 2 other interventions for Platysmal Bands. Completed, enrolled 80 participants across 8 sites.

Detailed Summary

Interventional phase 2 study to evaluate safety and efficacy of abobotulinumtoxinA for the treatment of platysmal bands.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlatysmal Bands
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedSep 6, 2019
Enrollment StartSep 25, 2019
Primary CompletionDec 30, 2019
Study CompletionJun 4, 2020
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6.8 years ago

Interventions

AbobotulinumtoxinA dose 1biological

Treatment of platysmal bands

Placeboother

Treatment of platysmal bands

AbobotulinumtoxinA dose 2biological

Treatment of platysmal bands

AbobotulinumtoxinA dose 3biological

Treatment of platysmal bands